Video
Dr. Logan Discusses Treatment Options in CLL
Author(s):
In Partnership With:
Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia.
Aaron Logan, MD, PhD, assistant professor of clinical medicine, UCSF Helen Diller Family Comprehensive Cancer Center, discusses treatment options for patients with chronic lymphocytic leukemia (CLL).
CLL remains the most common leukemia in adults, says Logan. This has led to a lot of innovative therapy, such as monoclonal agents and chemoimmunothearpy.
Additionally, patients with genetic abnormalities such as 17p deletion and p53 now have targeted agents like venetoclax (Venclexta), as these mutations do not respond well to chemoimmunotherapy.
Latest CME
View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Jun 6th 2025 - Jul 12th 2025
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Jun 6th 2025 - Jul 12th 2025
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Jun 5th 2025 - Jul 12th 2025
